Athanassios Argiris1, Shuli Li2, Panayiotis Savvides3, James P Ohr4, Jill Gilbert5, Marshall A Levine6, Arnab Chakravarti7, Missak Haigentz8, Nabil F Saba9, Chukwuemeka V Ikpeazu10, Charles J Schneider11, Harlan A Pinto12, Arlene A Forastiere13, Barbara Burtness14,15. 1. Thomas Jefferson University, Philadelphia, PA. 2. Dana Farber Cancer Institute, Boston, MA. 3. University of Arizona Cancer Center, Phoenix, AZ. 4. University of Pittsburgh, Pittsburgh, PA. 5. Vanderbilt University, Nashville, TN. 6. Greater Baltimore Medical Center, Baltimore, MD. 7. The Ohio State University Medical School, Columbus, OH. 8. Montefiore Medical Center, Bronx, NY. 9. Emory University, Atlanta, GA. 10. University of Miami, Miami, FL. 11. University of Pennsylvania, Philadelphia, PA. 12. Stanford University Medical Center, Stanford, CA. 13. Johns Hopkins University, Baltimore, MD. 14. Yale University School of Medicine, New Haven, CT. 15. Yale Cancer Center, New Haven, CT.
Abstract
PURPOSE: We evaluated the addition of bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Patients with chemotherapy-naïve (or with prior platinum as part of multimodal therapy completed ≥ 4 months earlier) recurrent or metastatic SCCHN were randomly assigned to receive a platinum-based chemotherapy doublet with or without bevacizumab 15 mg/kg given intravenously every 3 weeks until disease progression. Chemotherapy could be discontinued after six cycles if a maximum response was achieved. RESULTS: The study randomly assigned 403 patients. Median overall survival (OS) was 12.6 months with bevacizumab plus chemotherapy (BC) and 11.0 months with chemotherapy alone (hazard ratio, 0.87; 95% CI, 0.70 to 1.09; P = .22). At 2, 3, and 4 years, the OS rates were 25.2% v 18.1%, 16.4% v 10.0%, and 11.8% v 6.4% for BC versus chemotherapy, respectively. In an analysis of 365 eligible patients who started treatment, the hazard ratio was 0.82 (95% CI, 0.65 to 1.04; P = .10), with a median OS of 14.2 months on BC v 11.1 months on chemotherapy. Median progression-free survival with BC was 6.0 months v 4.3 months with chemotherapy (P = .0014). Overall response rates were 35.5% with BC and 24.5% with chemotherapy (P = .016). There was increased toxicity, including a higher rate of treatment-related grade 3 to 5 bleeding events (6.7% v 0.5%; P < .001) and treatment-related deaths (9.3% v 3.5%; P = .022) with BC versus chemotherapy. CONCLUSION: The addition of bevacizumab to chemotherapy did not improve OS but improved the response rate and progression-free survival with increased toxicities. These results encourage biomarker-driven studies of angiogenesis inhibitors with better toxicity profiles in select patients with SCCHN.
RCT Entities:
PURPOSE: We evaluated the addition of bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Patients with chemotherapy-naïve (or with prior platinum as part of multimodal therapy completed ≥ 4 months earlier) recurrent or metastatic SCCHN were randomly assigned to receive a platinum-based chemotherapy doublet with or without bevacizumab 15 mg/kg given intravenously every 3 weeks until disease progression. Chemotherapy could be discontinued after six cycles if a maximum response was achieved. RESULTS: The study randomly assigned 403 patients. Median overall survival (OS) was 12.6 months with bevacizumab plus chemotherapy (BC) and 11.0 months with chemotherapy alone (hazard ratio, 0.87; 95% CI, 0.70 to 1.09; P = .22). At 2, 3, and 4 years, the OS rates were 25.2% v 18.1%, 16.4% v 10.0%, and 11.8% v 6.4% for BC versus chemotherapy, respectively. In an analysis of 365 eligible patients who started treatment, the hazard ratio was 0.82 (95% CI, 0.65 to 1.04; P = .10), with a median OS of 14.2 months on BC v 11.1 months on chemotherapy. Median progression-free survival with BC was 6.0 months v 4.3 months with chemotherapy (P = .0014). Overall response rates were 35.5% with BC and 24.5% with chemotherapy (P = .016). There was increased toxicity, including a higher rate of treatment-related grade 3 to 5 bleeding events (6.7% v 0.5%; P < .001) and treatment-related deaths (9.3% v 3.5%; P = .022) with BC versus chemotherapy. CONCLUSION: The addition of bevacizumab to chemotherapy did not improve OS but improved the response rate and progression-free survival with increased toxicities. These results encourage biomarker-driven studies of angiogenesis inhibitors with better toxicity profiles in select patients with SCCHN.
Authors: Athanassios Argiris; Michalis V Karamouzis; William E Gooding; Barton F Branstetter; Shilong Zhong; Luis E Raez; Panayiotis Savvides; Marjorie Romkes Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: Michael K Gibson; Yi Li; Barbara Murphy; Maha H A Hussain; Ronald C DeConti; John Ensley; Arlene A Forastiere Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: A Argiris; A P Kotsakis; T Hoang; F P Worden; P Savvides; M K Gibson; R Gyanchandani; G R Blumenschein; H X Chen; J R Grandis; P M Harari; M S Kies; S Kim Journal: Ann Oncol Date: 2012-08-16 Impact factor: 32.976
Authors: Ezra E W Cohen; Darren W Davis; Theodore G Karrison; Tanguy Y Seiwert; Stuart J Wong; Sreenivasa Nattam; Mark F Kozloff; Joseph I Clark; Duen-Hwa Yan; Wen Liu; Carolyn Pierce; Janet E Dancey; Kerstin Stenson; Elizabeth Blair; Allison Dekker; Everett E Vokes Journal: Lancet Oncol Date: 2009-02-07 Impact factor: 41.316
Authors: H Mineta; K Miura; T Ogino; S Takebayashi; K Misawa; Y Ueda; I Suzuki; M Dictor; A Borg; J Wennerberg Journal: Br J Cancer Date: 2000-09 Impact factor: 7.640
Authors: Eve LoCastro; Ramesh Paudyal; Yousef Mazaheri; Vaios Hatzoglou; Jung Hun Oh; Yonggang Lu; Amaresha Shridhar Konar; Kira Vom Eigen; Alan Ho; James R Ewing; Nancy Lee; Joseph O Deasy; Amita Shukla-Dave Journal: Tomography Date: 2020-06
Authors: Aini Hyytiäinen; Wafa Wahbi; Otto Väyrynen; Kauko Saarilahti; Peeter Karihtala; Tuula Salo; Ahmed Al-Samadi Journal: Front Oncol Date: 2021-06-14 Impact factor: 6.244